All In Biotech

Investigational drug · Phase 3

Deucrictibant

Also called: PHVS416, PHA121, PHA-022121

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hereditary Angioedema (HAE), Hereditary Angioedema, Hereditary Angioedema Type I.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

3 still active

All registered trials

9

Any phase or sponsor naming "Deucrictibant"

First trial start

2022

Dec 28, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Deucrictibant", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hereditary Angioedema (HAE)
  • Hereditary Angioedema
  • Hereditary Angioedema Type I
  • Hereditary Angioedema Type II
  • Hereditary Angioedema Types I and II
  • Hereditary Angioedema Attack
  • Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2
  • Hereditary Angioedema - Type 3

Approved drugs for the same conditions: Hereditary angioedema · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Deucrictibant" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14 on PubMed

Also in development for Hereditary Angioedema (HAE)

  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • BW-20805Phase 21 trial

    Shanghai Argo Biopharmaceutical Co., Ltd. · Hereditary Angioedema (HAE)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.